Anticancer therapeutic strategies based on CDK inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 30, 2013, Pages 5327-5332

  Esposito, Luca ^a   Indovina, Paola ^b   Magnotti, Flora ^a   Conti, Daniele ^b   Giordano, Antonio ^a,b,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Temple University   (United States)

Author keywords

Anticancer therapeutics; Cancer; CDK inhibitors; CDKs; Cell cycle

Indexed keywords

AT 7519; ATP COMPETITIVE CYCLIN DEPENDENT KINASE INHIBITOR; CY 202; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; FLAVOPIRIDOL; NON ATP COMPETITIVE CYCLIN DEPENDENT KINASE INHIBITOR; P 276 00; R 547; ROSCOVITINE; UNCLASSIFIED DRUG; VORINOSTAT; ZK 304709;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE REGULATION; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 84881361773     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990377     Document Type: Review

References (57)

1. Malumbres M. Physiological relevance of cell cycle kinases. Physiol Rev 2011; 91(3): 973-1007.
2. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30(11): 630-41.
3. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008; 14(2): 159-69.
4. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8(7): 547-66.
5. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9(3): 153-66.
6. Canavese M, Santo L, Raje N. Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther 2012; 13(7): 451-7.
7. Henley SA, Dick FA. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div 2012; 7(1): 10.
8. Rizzolio F, Tuccinardi T, Caligiuri I, Lucchetti C, Giordano A. CDK inhibitors: from the bench to clinical trials. Curr Drug Targets 2010; 11(3): 279-90.
9. Pucci B, Giordano A. Cell cycle and cancer. Clin Ter 1999; 150(2): 135-41.
10. Geng Y, Yu Q, Sicinska E, et al. Cyclin E ablation in the mouse. Cell 2003; 114(4): 431-43.
11. Bagella L, Sun A, Tonini T, et al. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene 2007; 26(13): 1829-39.
12. Morgan DO. SnapShot: cell-cycle regulators I. Cell 2008; 135(4): 764-e1.
13. Morgan DO. SnapShot: Cell-cycle regulators II. Cell 2008; 135(5): 974-e1.
14. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602(1): 73-87.
15. Perez de Castro I, de Carcer G, Malumbres M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 2007; 28(5): 899-912.
16. Romano G, Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle 2008; 7(23): 3664-8.
17. Garriga J, Xie H, Obradovic Z, Grana X. Selective control of gene expression by CDK9 in human cells. J Cell Physiol 2010; 222(1): 200-8.
18. Yokoyama H, Gruss OJ, Rybina S, et al. Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate. J Cell Biol 2008; 180(5): 867-75.
19. Hu D, Valentine M, Kidd VJ, Lahti JM. CDK11(p58) is required for the maintenance of sister chromatid cohesion. J Cell Sci 2007; 120(Pt 14): 2424-34.
20. Chandramouli A, Shi J, Feng Y, et al. Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice. Carcinogenesis 2007; 28(9): 2028-35.
21. Cirillo D, Pentimalli F, Giordano A. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors. Curr Med Chem 2011; 18(19): 2854-66.
22. Futatsugi A, Utreras E, Rudrabhatla P, Jaffe H, Pant HC, Kulkarni AB. Cyclin-dependent kinase 5 regulates E2F transcription factor through phosphorylation of Rb protein in neurons. Cell Cycle 2012; 11(8): 1603-10.
23. Lilja L, Yang SN, Webb DL, Juntti-Berggren L, Berggren PO, Bark C. Cyclin-dependent kinase 5 promotes insulin exocytosis. J Biol Chem 2001; 276(36): 34199-205.
24. Moore NL, Narayanan R, Weigel NL. Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids 2007; 72(2): 202-9.
25. Jessen BA, Lee L, Koudriakova T, et al. Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors. J Appl Toxicol 2007; 27(2): 133-42.
26. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109(2): 399-404.
27. Saturno G, Pesenti M, Cavazzoli C, et al. Expression of serine/threonine protein-kinases and related factors in normal monkey and human retinas: the mechanistic understanding of a CDK2 inhibitor induced retinal toxicity. Toxicol Pathol 2007; 35(7): 972-83.
28. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008; 29(1): 16-21.
29. Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 2007; 6(3): 918-25.
30. Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther 2007; 6(3): 926-34.
31. Squires MS, Feltell RE, Wallis NG, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther 2009; 8(2): 324-32.
32. DePinto W, Chu XJ, Yin X, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006; 5(11): 2644-58.
33. Siemeister G, Luecking U, Wagner C, Detjen K, McCoy C, Bosslet K. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. Biomed Pharmacother 2006; 60(6): 269-72.
34. Scholz A, Wagner K, Welzel M, et al. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model. Gut 2009; 58(2): 261-70.
35. Luke JJ, D'Adamo DR, Dickson MA, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res 2012; 18(9): 2638-47.
36. Nguyen DM, Schrump WD, Tsai WS, et al. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent deathsignaling pathway. J Thorac Cardiovasc Surg 2003; 125(5): 1132-42.
37. Nguyen DM, Schrump WD, Chen GA, et al. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004; 10(5): 1813-25.
38. Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002; 16(7): 1331-43.
39. Gao N, Dai Y, Rahmani M, Dent P, Grant S. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol 2004; 66(4): 956-63.
40. Rosato RR, Almenara JA, Yu C, Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004; 65(3): 571-81.
41. Rosato RR, Almenara JA, Kolla SS, et al. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Mol Cancer Ther 2007; 6(2): 692-702.
42. Huang JM, Sheard MA, Ji L, Sposto R, Keshelava N. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrugresistant neuroblastoma cell lines with mutant TP53. Mol Cancer Ther 2010; 9(12): 3289-301.
43. Orzaez M, Gortat A, Mondragon L, Bachs O, Perez-Paya E. ATP-noncompetitive inhibitors of CDK-cyclin complexes. Chem Med Chem 2009; 4(1): 19-24.
44. McInnes C. Progress in the evaluation of CDK inhibitors as antitumor agents. Drug Discov Today 2008; 13(19-20): 875-81.
45. Okorokov AL. p53 in a crosstalk between DNA repair and cell cycle checkpoints. Cell Cycle 2003; 2(3): 233-5.
46. Morgan SE, Kastan MB. p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 1997; 71: 1-25.
47. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997; 243(1-2): 518-26.
48. Arris CE, Boyle FT, Calvert AH, et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem 2000; 43(15): 2797-804.
49. Luciani MG, Hutchins JR, Zheleva D, Hupp TR. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol 2000; 300(3): 503-18.
50. Jeffrey PD, Russo AA, Polyak K, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995; 376(6538): 313-20.
51. Canela N, Orzaez M, Fucho R, et al. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A. J Biol Chem 2006; 281(47): 35942-53.
52. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10(3): 310-5.
53. Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, Kaelin WG, Jr. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol 1996 Dec; 16(12): 6623-33.
54. Andrews MJ, McInnes C, Kontopidis G, et al. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org Biomol Chem 2004; 2(19): 2735-41.
55. Zheleva DI, McInnes C, Gavine AL, Zhelev NZ, Fischer PM, Lane DP. Highly potent p21(WAF1)-derived peptide inhibitors of CDKmediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. J Pept Res 2002; 60(5): 257-70.
56. Atkinson GE, Cowan A, McInnes C, Zheleva DI, Fischer PM, Chan WC. Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe. Bioorg Med Chem Lett 2002; 12(18): 2501-5.
57. Kontopidis G, Andrews MJ, McInnes C, et al. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design. Chem Med Chem 2009; 4(7): 1120-8.